These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 21584931

  • 1. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
    Bonney DK, Htwe EE, Turner A, Kelsey A, Shabani A, Hughes S, Hughes I, Wynn RF.
    Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
    [Abstract] [Full Text] [Related]

  • 2. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
    Czyzewski K, Styczynski J, Krenska A, Debski R, Zajac-Spychala O, Wachowiak J, Wysocki M.
    Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
    [Abstract] [Full Text] [Related]

  • 3. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation.
    Twombley K, Pokala H, Ardura MI, Harker-Murray P, Johnson-Welch SF, Weinberg A, Seikaly M.
    Pediatr Transplant; 2012 Sep; 16(6):E201-9. PubMed ID: 22646132
    [Abstract] [Full Text] [Related]

  • 4. [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation].
    Aimoto M, Yamane T, Inoue A, Momose D, Moriguchi-Aimoto R, Wada-Inoue E, Okamoto S, Koh H, Nakane T, Takeoka Y, Akahori-Nakamae M, Nishiki-Kosaka S, Terada Y, Nakamae H, Koh KR, Nakao T, Ohsawa M, Hino M.
    Rinsho Ketsueki; 2010 Dec; 51(12):1775-80. PubMed ID: 21258188
    [Abstract] [Full Text] [Related]

  • 5. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
    Scand J Infect Dis; 2007 Dec; 39(3):235-44. PubMed ID: 17366054
    [Abstract] [Full Text] [Related]

  • 6. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab.
    Kordelas L, Trenschel R, Koldehoff M, Elmaagacli A, Beelen DW.
    Onkologie; 2008 Dec; 31(12):691-3. PubMed ID: 19060508
    [Abstract] [Full Text] [Related]

  • 7. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.
    Clin Transplant; 2013 Dec; 27(4):E491-7. PubMed ID: 23781897
    [Abstract] [Full Text] [Related]

  • 8. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges.
    Kittan NA, Beier F, Kurz K, Niller HH, Egger L, Jilg W, Andreesen R, Holler E, Hildebrandt GC.
    Transpl Infect Dis; 2011 Oct; 13(5):524-30. PubMed ID: 21395956
    [Abstract] [Full Text] [Related]

  • 9. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
    [Abstract] [Full Text] [Related]

  • 10. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
    Kasow KA, Leung W, Horwitz EM, Woodard P, Handgretinger R, Hale GA.
    Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
    [Abstract] [Full Text] [Related]

  • 11. Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study.
    Wu M, Sun J, Zhang Y, Huang F, Zhou H, Fan Z, Xuan L, Yu G, Guo X, Dai M, Feng R, Liu Q.
    Bone Marrow Transplant; 2016 Mar; 51(3):456-8. PubMed ID: 26595071
    [No Abstract] [Full Text] [Related]

  • 12. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
    Sato E, Ohga S, Kuroda H, Yoshiba F, Nishimura M, Nagasawa M, Inoue M, Kawa K.
    Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
    [Abstract] [Full Text] [Related]

  • 13. The emergence of CD20-/CD19- tumor cells after rituximab therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disorder complicated with hemophagocytic lymphohistiocytosis.
    Yamamoto N, Nishimura N, Takeuchi M, Ito T, Yokozaki H, Hirase S, Kubokawa I, Mori T, Yanai T, Hayakawa A, Takeshima Y, Nishio H, Matsuo M, Imadome K, Iijima K.
    Eur J Pediatr; 2014 Dec; 173(12):1615-8. PubMed ID: 24169729
    [Abstract] [Full Text] [Related]

  • 14. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
    Worth A, Conyers R, Cohen J, Jagani M, Chiesa R, Rao K, Goulden N, Veys P, Amrolia PJ.
    Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
    [Abstract] [Full Text] [Related]

  • 15. Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system.
    van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J.
    Pediatr Blood Cancer; 2008 Apr; 50(4):886-8. PubMed ID: 17668865
    [Abstract] [Full Text] [Related]

  • 16. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis.
    Balamuth NJ, Nichols KE, Paessler M, Teachey DT.
    J Pediatr Hematol Oncol; 2007 Aug; 29(8):569-73. PubMed ID: 17762500
    [Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus infection and lymphoproliferative disorder after hematopoietic cell transplantation.
    Zhong Y.
    Clin J Oncol Nurs; 2012 Apr; 16(2):211-4. PubMed ID: 22459531
    [Abstract] [Full Text] [Related]

  • 18. Treatment of rare co-occurrence of Epstein-Barr virus-driven post-transplant lymphoproliferative disorder and hemophagocytic lymphohistiocytosis after allogeneic stem cell transplantation.
    Weber T, Wickenhauser C, Monecke A, Gläser C, Stadler M, Desole M, Ligeti K, Behrmann C, Müller-Tidow C, Müller LP.
    Transpl Infect Dis; 2014 Dec; 16(6):988-92. PubMed ID: 25179757
    [Abstract] [Full Text] [Related]

  • 19. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J, Einsele H, Gil L, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [Abstract] [Full Text] [Related]

  • 20. Treatment of Epstein-Barr virus--associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: a case report and literature review.
    Zhu K, Chen J, Chen S.
    Hematology; 2005 Oct; 10(5):365-70. PubMed ID: 16273722
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.